Damora Therapeutics, Inc. (DMRA)
NasdaqCM · USD · Healthcare · Biotechnology
$21.26 (+0.81%) as of
Key statistics
- Market cap
- 1.31B
- Forward P/E
- -9.79
- EPS (TTM)
- -0.25
- Dividend yield
- 0.00%
- 52-week range
- 4.95 – 38.33
- Beta
- 1.43
- Profit margin
- 0.00%
- Analyst target
- $46.89
- Volume
- 641.72k
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Waltham, MA, United States
- Employees
- 7
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.